Cosmetic peptide
Matrixyl (Palmitoyl Pentapeptide-4, formerly Palmitoyl Pentapeptide-3) is a matrikine peptide (Pal-KTTKS) used in anti-wrinkle cosmetics, originally launched by Sederma SAS in 2000. It consists of five amino acids linked to a 16-carbon palmitic acid chain for skin penetration. It is widely available in over-the-counter skincare products and is one of the most researched cosmetic peptides, with clinical evidence for modest improvements in fine lines and wrinkles.
Present clinical evidence for cosmetic use without overstating efficacy. Matrixyl is a cosmetic ingredient, not a drug. Do not publish dosing protocols or sourcing instructions. Track claims against published clinical data.
A 12-week double-blind, placebo-controlled, split-face randomized clinical study (n=93, Caucasian females aged 35-55) showed that topical 3 ppm pal-KTTKS provided significant improvement in fine lines and wrinkles vs. placebo, measured by both quantitative technical analysis and expert grader image analysis (Robinson et al., Int J Cosmet Sci, 2005).
In vitro studies demonstrate palmitoyl pentapeptide-4 activates neosynthesis of extracellular matrix macromolecules including collagen, providing a mechanistic basis for its anti-wrinkle effect.
A 2014 study characterized the dermal stability and in vitro skin permeation of KTTKS and palmitoyl-KTTKS, confirming the palmitoyl chain improves peptide penetration through skin lipid structures (Biomol Ther, 2014).
Matrixyl is classified as a cosmetic ingredient (OTC) with no FDA drug approval. It is widely marketed in skincare products with collagen stimulation claims.
Evidence level: Peer reviewed
Sources: PubMed / NCBI, PubMed / NCBI
Cite the Robinson et al. 2005 clinical study directly. The evidence supports modest improvement in fine lines/wrinkles in a controlled trial. Do not overstate as equivalent to prescription retinoids or procedures.
Evidence level: Market observation
Sources: Wikipedia, PubMed / NCBI
Track market availability without endorsing specific products. Matrixyl is a cosmetic ingredient, not an FDA-approved drug. Do not publish sourcing or purchasing guidance.
Evidence level: Peer reviewed
Sources: PubMed / NCBI, Wikipedia
Supported by in vitro permeation studies. This is mechanistic evidence, not clinical efficacy proof.
Free report
Use the same checklist Peptide Report uses to separate Matrixyl (Palmitoyl Pentapeptide-4) claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Source records are stored in the repo and linked from each claim.
Argireline (Acetyl Hexapeptide-8, formerly Acetyl Hexapeptide-3) is a synthetic hexapeptide fragment of SNAP-25, a prote...
Evidence review5-Amino-1MQ (5-amino-1-methylquinoline) is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enz...
Regulatory watchAOD-9604 is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone (hGH) residues 177-191,...
Regulatory watchBPC-157 is widely discussed online in injury recovery and performance communities, but the public evidence and regulator...
Regulatory watchStay informed